VILON

Anti-Aging & LongevityResearch Only

Intriguing laboratory findings and some promising human data, but the research base remains narrow and geographically concentrated. The lack of randomized controlled trials makes it difficult to assess true clinical potential.

Primarily studied by aging researchers and immunologists investigating thymic involution and immune senescence in elderly populations.

FDA Status

Research Only

Since Feb 2026

Evidence

Strong

Studies

20 total, 4 human

What is VILON?

This two-amino-acid peptide represents one of the smallest bioregulatory compounds studied for immune system aging. Derived from thymus tissue research, Vilon has attracted attention from gerontologists investigating why immune function declines with age. Russian researchers have conducted most studies on this peptide, particularly in elderly populations with metabolic disorders.

Vilon appears to act as a genetic switch that can reactivate dormant DNA regions in aging immune cells, particularly those that control T-cell production in the thymus gland. The peptide seems to influence chromatin structure - essentially helping tightly wound DNA in old cells become accessible again for normal immune cell development. This process may restore some of the thymus gland's ability to produce new T-cells, which typically declines sharply after puberty.

What the Research Shows

Twenty studies provide a reasonable foundation, but the absence of randomized controlled trials and limited geographic diversity in research groups weakens confidence in clinical applications.

Based on 20 total studies (6 human studies, 0 RCTs), VILON peptides demonstrated effects on immune function in laboratory and patient populations, including increased CD5 expression and T-cell differentiation in thymic cultures, promotion of thymocyte proliferation, heterochromatin reactivation in elderly lymphocytes, and improvements in coagulation, immune markers, and insulin requirements in elderly diabetic patients. However, the absence of randomized controlled trials limits the strength of evidence for clinical efficacy.